Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01986348 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01986348 is a Phase 2 study that was terminated before completion, run by Karyopharm Therapeutics. The registered enrollment target is 76 participants.
The verdict
NCT01986348, a Phase 2 study, was terminated before completion, sponsored by Karyopharm Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
Interventions
- DRUG Selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-03-03 |
| Est. Completion | 2020-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01986348
The ClinicalTrials.gov registry entry for NCT01986348 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selinexor is the first listed.
NCT01986348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01986348 about?
NCT01986348 is a clinical study titled "Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas". This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.
What is the current status of trial NCT01986348?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-03-03. Estimated completion is 2020-01-23.
What interventions are being tested in trial NCT01986348?
The interventions under investigation include: Selinexor (DRUG).
Who is sponsoring clinical trial NCT01986348?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.